ClinicalTrials.Veeva

Menu

Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Allergan logo

Allergan

Status and phase

Completed
Phase 3

Conditions

Glaucoma
Ocular Hypertension

Treatments

Drug: brimonidine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00168363
190342-022

Details and patient eligibility

About

This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension

Enrollment

207 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ocular hypertension or glaucoma in both eyes
  • currently treated with brimonidine
  • requires IOP-lowering therapy in both eyes

Exclusion criteria

  • uncontrolled systemic disease
  • known allergy or sensitivity to brimonidine

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems